1-3 of 3
Lisa Johnson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Magrolimab plus azacitidine vs physician’s choice for untreated TP53 -mutated acute myeloid leukemia: the ENHANCE-2 study

Open Access
Clinical Trials & Observations
Joshua F. Zeidner, David A. Sallman, Christian Récher, Naval G. Daver, Anskar Y. H. Leung, Devendra K. Hiwase, Marion Subklewe, Thomas Pabst, Pau Montesinos, Richard A. Larson, Lindsay Wilde, Anoop K. Enjeti, Ichiro Kawashima, Cristina Papayannidis, Jenny O’Nions, Lisa Johnson, Mei Dong, Julie Huang, Taravat Bagheri, Gal Hacohen Kleiman, Calvin Lee, Paresh Vyas
Journal: Blood
Blood (2025) 146 (5): 590–600.
https://doi.org/10.1182/blood.2024027408
Published: 2025
Includes: Supplemental data
Journal Articles

The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy

Open Access
Clinical Trials & Observations
Naval Daver, Paresh Vyas, Gerwin Huls, Hartmut Döhner, Sébastien Maury, Jan Novak, Cristina Papayannidis, Carmen Martínez Chamorro, Pau Montesinos, Rabin Niroula, Pierre Fenaux, Jordi Esteve, Shang-Ju Wu, Adrien De Voeght, Jiri Mayer, Peter J. M. Valk, Lisa Johnson, Mei Dong, Ke Liu, Sowmya Kuwahara, Kenneth Caldwell, Guru Subramanian Guru Murthy
Journal: Blood
Blood (2025) 146 (5): 601–611.
https://doi.org/10.1182/blood.2024027506
Published: 2025
Includes: Supplemental data
Journal Articles

Nature of Clinical Response and Depth of Molecular Response in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Treated with Magrolimab with Azacitidine

Free
Lisa Johnson, Yajia Zhang, Biao Li, Lisa Aviles, Indu Lal, Giri Ramsingh, Naval Daver, Paresh Vyas, David A. Sallman
Journal: Blood
Blood (2022) 140 (Supplement 1): 6934–6935.
https://doi.org/10.1182/blood-2022-160337
Published: 2022